Clinical Trial: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA(R)): A U.S. Pragmatic Multicenter Study (STREAM)

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448610) titled 'ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA(R)): A U.S. Pragmatic Multicenter Study (STREAM)' on Feb. 26.

Brief Summary: The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA(R)). U.S. Pragmatic Multicenter Study (STREAM).

Study Start Date: July 01, 2026

Study Type: INTERVENTIONAL

Condition: Spinal Muscular Atrophy

Intervention: DRUG: Onasemnogene Abeparvovec...